Form 4: Oscar Health Director Boosts Stock Holdings

Oscar Health, Inc. Director David Plouffe elected to receive 1,257 deferred stock units in lieu of cash retainer payments for his board service, aligning his interests further with shareholders.

Summary

• David Plouffe, a Director of Oscar Health, Inc. (OSCR), acquired 1,257 deferred stock units (DSUs).
• These DSUs were received in lieu of cash retainer payments for his service on the Issuer's board of directors, pursuant to the Issuer's Amended and Restated Deferred Compensation Plan for Directors.
• Each DSU represents a right to receive one share of Oscar Health's Class A common stock.
• The transaction occurred on January 8, 2026.
• The price used to calculate the number of DSUs was $16.9, which was the closing price of the Class A common stock on January 8, 2026.
• The DSUs are 100% vested on the grant date.
• Settlement will occur for cash or Class A common stock, at the Issuer's discretion, within 45 days of termination of service, a change in control, death, or disability.
• Following this transaction, David Plouffe beneficially owns a total of 5,393 derivative securities (DSUs).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director choosing equity over cash generally indicates confidence in the company's future and aligns their interests with shareholders. However, it's a routine compensation event, not a major strategic or financial announcement.

Positives

• Director David Plouffe's election to receive deferred stock units instead of cash demonstrates increased alignment of his interests with those of the company's shareholders.
• The immediate 100% vesting of the deferred stock units on the grant date provides certainty of ownership for the director.

Negatives

• The Issuer retains discretion to settle the deferred stock units in either cash or Class A common stock, which could introduce some uncertainty for the reporting person regarding the form of future payment.

Risks

• The value of the deferred stock units is tied to the future performance of Oscar Health's Class A common stock, exposing the director to market fluctuations.
• The timing and form of settlement (cash or stock) are at the Issuer's discretion, which could impact the director's financial planning.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's operational or financial performance, focusing solely on an insider compensation transaction.

Industry Context

It is a common practice for directors of publicly traded companies to receive a portion of their compensation in equity or equity-linked instruments, such as deferred stock units, to align their interests with long-term shareholder value. This practice is prevalent across various industries, including healthcare technology.

Comparison to Industry Standards

• The practice of compensating directors with deferred stock units in lieu of cash is a standard corporate governance practice among U.S. public companies, including those in the health insurance and technology sectors like Oscar Health.
• Many companies, such as UnitedHealth Group (UNH) or Cigna (CI), also utilize equity-based compensation for their non-employee directors to foster long-term commitment and align incentives with shareholder returns.
• The immediate 100% vesting on the grant date for such units is also a common feature, ensuring directors have immediate ownership rights, although settlement is typically deferred until separation from service or other specified events.

Corporate Governance

Stakeholder Impact

• Shareholders: The election by a director to receive equity compensation instead of cash can be viewed positively as it increases the director's stake in the company, potentially aligning their long-term interests more closely with those of other shareholders.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The deferred stock units will be settled for cash or shares of Class A common stock, at the Issuer's discretion, within 45 days of the first to occur of termination of service, a change in control, death, or disability.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director elected to receive deferred stock units as part of their compensation. While it indicates a director's continued alignment with the company, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Oscar Health's business.

Keywords

Oscar Health, OSCR, David Plouffe, Director Compensation, Deferred Stock Units, Insider Transaction, SEC Form 4, Equity Compensation, Corporate Governance